JOURNAL OF HEALTHCARE SCIENCES

Volume 5 Issue 12 2025, Article ID: JOHS2025001154

http://dx.doi.org/10.52533/JOHS.2025.51219

e-ISSN: 1658-8967

Review

Identification and Management of Attention Deficit Hyperactivity Disorder in Adults

Suhail Abdalhameed Khan[1*], Khalid Hamdi Bin Yousef[2], Jumana Osama Alaama[3], Amal Abdulmunam Alkhunizi[4], Osama Homood Aldoweesh[5], Mohammed Nael Alazwary[6], Mohammed Salman Almadani[7], Hussain Ali Al Eid[8]

[1] *Department of Psychiatry, East Jeddah Hospital, Jeddah, Saudi Arabia*
[2] *Behavior and Developmental Disorder Center, Ministry of Health, Taif, Saudi Arabia*
[3] *Department of Psychiatry, Eradah Complex And Mental Health, Jeddah, Jeddah, Saudi Arabia*
[4] *Department of Psychiatry, Ministry of Health, Dammam, Saudi Arabia*
[5] *College of Medicine, Qassim University, Qassim, Saudi Arabia*
[6] *Department of Psychiatry, Ministry of Defense, Riyadh, Saudi Arabia*
[7] *Department of Family Medicine, Presidency of State Security, Riyadh, Saudi Arabia*
[8] *Department of Intensive Care Unit, Ministry of Health, Qatif, Saudi Arabia*

Correspondence should be addressed **Suhail Abdalhameed Khan**, Department of Psychiatry, East Jeddah Hospital, Jeddah, Saudi Arabia, Email: drsuhail_911@hotmail.com

Received: 01 December 2025, Accepted: 23 December 2025, Published: 24 December 2025.

Abstract

Attention-Deficit Hyperactivity Disorder (ADHD) persists in adulthood in a significant portion of individuals initially diagnosed in childhood, yet recognition and management in adults remain inconsistent across clinical settings. Adult presentations often differ from pediatric profiles, with less observable hyperactivity and more internalized symptoms such as distractibility, restlessness, and executive dysfunction. Misdiagnosis or underdiagnosis is common, especially in populations where symptoms overlap with mood disorders, anxiety, or trauma-related conditions. Gender, cultural norms, and the absence of validated developmental histories further complicate diagnostic accuracy. Pharmacological treatments, particularly stimulant medications, remain the most studied and widely prescribed option, showing strong efficacy in reducing core symptoms. However, long-term use is limited by side effects, adherence issues, and reduced functional gains when used in isolation. Non-stimulant options and psychosocial interventions such as cognitive-behavioral therapy offer complementary benefits, especially in targeting functional impairments like time management, emotional regulation, and self-esteem. Combination therapy tends to yield more durable and comprehensive outcomes compared to monotherapies. Long-term management requires flexible, patient-centered approaches that account for shifting life demands and personal goals. Digital tools, psychoeducation, and structured behavioral interventions play increasingly supportive roles in promoting autonomy and continuity of care. A sustained therapeutic alliance and functional goal setting are central to long-term success, as many adults with ADHD struggle with a history of negative self-perception and disengagement from mental health services. Comprehensive care models integrating medical, psychological, and social dimensions are essential to address the heterogeneity of adult ADHD and promote improved quality of life across the lifespan.

Keywords: ADHD, adult diagnosis, pharmacological treatment, cognitive-behavioral therapy, long-term

Introduction

Attention Deficit Hyperactivity Disorder (ADHD) is a neurodevelopmental disorder characterized by persistent patterns of inattention, hyperactivity, and impulsivity that interfere with functioning across multiple domains of life. Although traditionally associated with childhood, it is now widely recognized that ADHD frequently persists in adulthood, affecting approximately 2.5% of adults globally (1). The recognition of adult ADHD has grown over the past two decades, yet it remains underdiagnosed and undertreated, partly due to a historical bias that considered it a pediatric condition. In adults, the symptom presentation often shifts from overt hyperactivity to more subtle manifestations such as restlessness, executive dysfunction, and emotional dysregulation, complicating clinical identification.

Diagnosing ADHD in adults poses unique challenges. Unlike children, adults are more likely to be present with comorbid psychiatric disorders such as anxiety, depression, substance use disorders, and personality disorders, which can obscure or mimic ADHD symptoms (2). Furthermore, retrospective assessment of childhood symptoms are unreliable due to memory bias and a lack of historical documentation. Diagnostic tools tailored for adults, such as the Adult ADHD Self-Report Scale (ASRS), have improved sensitivity and specificity, yet they are often used inconsistently in clinical practice (3). Additionally, cultural and gender-related factors may influence the expression and recognition of symptoms, contributing further to the underdiagnosis of women and individuals from minority backgrounds.

Management of adult ADHD requires a multimodal approach. Pharmacological treatment, particularly the use of stimulant medications such as methylphenidate and amphetamines, has demonstrated strong efficacy in reducing core symptoms. Non-stimulant options, including atomoxetine and certain antidepressants, offer alternatives for individuals with contraindications or intolerances to stimulants. However, medication alone is often insufficient. Psychosocial interventions, including cognitive-behavioral therapy (CBT), skills training, and psychoeducation, play a critical role in improving functional outcomes, such as occupational performance, time management, and interpersonal relationships (4). These interventions are particularly valuable for addressing the executive function deficits and emotional dysregulation often reported by adults with ADHD. Misconceptions about the disorder contribute to stigma, delays in diagnosis, and inadequate access to care. Health systems are often poorly equipped to support adults with ADHD, with services primarily oriented toward children and adolescents. Furthermore, there is a lack of consensus on long-term treatment strategies, particularly concerning the sustained use of stimulant medications, monitoring protocols, and transitioning care from adolescence to adulthood.

Review

The identification and management of ADHD in adults continue to present significant clinical challenges, particularly due to the heterogeneity of symptom expression and the frequent presence of comorbid psychiatric conditions. Adults with ADHD often experience difficulties in executive functioning, emotional regulation, and time management, which may not align neatly with the traditional symptom clusters defined in diagnostic manuals. Consequently, underdiagnosis remains a prevalent issue, especially among populations such as women and ethnic minorities who may present with less overt hyperactivity or impulsivity (5).

Management strategies have evolved to recognize the need for personalized, multimodal approaches. Pharmacotherapy remains a cornerstone, but the long-term efficacy and tolerability of stimulant medications in adults are still debated. Importantly, non-pharmacological interventions such as CBT have shown promise in improving functional impairments beyond symptom reduction. These therapies help patients develop coping strategies, organizational skills, and resilience in managing daily challenges. Integrating behavioral interventions with pharmacological treatment appears to yield superior outcomes compared to

http://dx.doi.org/10.52533/JOHS.2025.51219

either modality alone (6). However, access to such comprehensive care is limited by systemic barriers, including a lack of trained professionals and fragmented services across the adult mental healthcare continuum.

Challenges in Diagnosing ADHD in Adult Populations

Diagnosing Attention-Deficit Hyperactivity Disorder in adults is complicated by the evolving nature of symptom expression, overlapping psychiatric conditions, and structural gaps in clinical assessment protocols. In early life, ADHD tends to manifest through externalizing behaviors such as hyperactivity or impulsivity, which often trigger school-based referrals. By adulthood, however, symptomatology typically shifts to more internalized experiences like distractibility, emotional dysregulation, restlessness, and chronic disorganization. These more subtle signs are frequently misattributed to stress, personality traits, or comorbid conditions, which can result in diagnostic overshadowing (7).

The reliance on retrospective childhood symptom reporting presents a major barrier. Most diagnostic systems, including DSM-5, require evidence of symptoms prior to age 12. Adults being assessed may lack accurate recollection of early behaviors or have limited access to informant histories from parents or teachers. This becomes especially problematic for individuals raised in socioeconomically disadvantaged environments or within cultures where neurodevelopmental concerns were overlooked or dismissed. Clinical interviews are therefore often built on uncertain foundations, and objective data sources, such as school records or caregiver input, are not always obtainable (8).

Gender-specific biases further complicate diagnostic clarity. Women with ADHD are frequently diagnosed later in life, often during evaluations for mood or anxiety disorders. The internalizing presentation common among females tends to be less disruptive and thus less likely to prompt early clinical intervention. Consequently, many women remain undiagnosed until academic or occupational stressors in adulthood force them to seek help. Misdiagnosis with conditions like borderline personality disorder or generalized anxiety disorder remains a recurring issue, leading to delays in accessing appropriate treatment pathways (9, 10).

Diagnostic tools themselves, while improving, are not without limitation. Many self-report scales used in adult populations, such as the ASRS or Conners' Adult ADHD Rating Scales, depend heavily on the individual's insight and ability to self-reflect—faculties that are themselves compromised in some adults with executive dysfunction. Furthermore, the criteria are often narrowly aligned with male pediatric symptom profiles, despite mounting evidence suggesting that ADHD manifests heterogeneously across the lifespan. This rigidity reduces diagnostic sensitivity in adults whose symptom patterns do not conform to the prototypical model. Clinicians trained predominantly in child psychiatry may also feel less confident applying these tools to adult presentations, creating inconsistencies in clinical practice (11).

Comorbidity adds another dimension of diagnostic complexity. Studies consistently show high rates of co-occurring psychiatric disorders among adults with ADHD, particularly depression, anxiety disorders, substance use disorders, and bipolar spectrum conditions. These conditions not only mask ADHD symptoms but can also lead clinicians to prioritize other diagnoses perceived as more urgent or better understood. Differential diagnosis thus becomes a nuanced and often uncertain process, in which the core features of ADHD may be interpreted as secondary to mood instability, trauma-related dysregulation, or addiction-related impairments. In many cases, the interplay between ADHD and comorbidities is bidirectional, complicating the clinical picture further and influencing treatment response.

Comparative Effectiveness of Pharmacological and Non-Pharmacological Treatments

The therapeutic landscape for adult ADHD incorporates a diverse array of treatment modalities, yet the comparative effectiveness between

http://dx.doi.org/10.52533/JOHS.2025.51219

pharmacological and non-pharmacological approaches remains a focal point in clinical decision-making. Stimulant medications, particularly formulations of methylphenidate and amphetamine, consistently demonstrate strong effect sizes in reducing core ADHD symptoms. Their mechanism of action—enhancing dopaminergic and noradrenergic transmission in the prefrontal cortex—directly targets the neurobiological substrates implicated in attention regulation and impulse control. Meta-analyses of randomized controlled trials have confirmed the short-term superiority of stimulants over placebo, with clinically meaningful symptom reduction achieved in a majority of adults receiving adequate dosing and titration (12).

The advantages of pharmacotherapy often taper when treatment goals extend beyond symptom suppression to include improvements in occupational functioning, emotional self-regulation, or interpersonal relationships. Non-stimulant medications such as atomoxetine, guanfacine, and certain antidepressants offer alternatives where stimulants are contraindicated or poorly tolerated, though their effect sizes tend to be smaller and onset of action slower. Moreover, tolerability profiles vary widely. Side effects—ranging from insomnia and appetite loss to cardiovascular concerns—require careful monitoring, particularly in adults with complex medical histories. Long-term adherence remains suboptimal, often due to perceived inefficacy in addressing the broader psychosocial impairments associated with the disorder (13).

CBT adapted for adult ADHD has emerged as the most extensively studied non-pharmacological intervention. Structured programs focusing on time management, cognitive restructuring, and coping strategies offer functional improvements that pharmacological treatments may not address. Evidence from well-designed trials suggests that CBT significantly improves executive functioning, emotion regulation, and overall quality of life, especially when delivered in conjunction with medication. Importantly, gains from CBT appear more durable over time, with lower relapse rates in follow-up assessments compared to medication-only groups. This durability is attributed to the acquisition of skills rather than reliance on neurochemical modulation (14).

Other behavioral approaches, including mindfulness-based interventions, dialectical behavior therapy components, and coaching models, have gained interest but remain less substantiated by large-scale trials. These modalities often appeal to patients seeking holistic or self-directed management options and may serve as adjuncts for individuals with partial medication responses. However, variability in program structure and outcome measures has made cross-study comparisons difficult, limiting their generalizability.

When examining treatment impact on functional domains such as work productivity, academic performance, and interpersonal stability, combination therapy appears to yield the most consistent benefits. Integrating pharmacological treatment with structured behavioral interventions enhances both symptom control and functional capacity, creating a more comprehensive treatment effect. Notably, patient preference plays a significant role in adherence and long-term outcomes. Adults often weigh treatment decisions against perceived stigma, past experiences with mental health care, and expectations of autonomy. Shared decision-making, therefore, becomes an essential component in optimizing individualized treatment plans, especially in a population where late diagnosis and prior mismanagement are common features (15).

Long-Term Management Strategies and Patient-Centered Approaches

Sustaining treatment efficacy over the long term in adult ADHD requires more than acute symptom control. Longitudinal outcomes are influenced by a complex interplay of treatment continuity, life transitions, evolving functional demands, and shifting patient priorities. Persistence with stimulant medication often declines over time, with studies indicating dropout rates as high as 50% within the first year of initiation. This attrition is not solely

http://dx.doi.org/10.52533/JOHS.2025.51219

driven by adverse effects or lack of efficacy; rather, many adults disengage from treatment due to rigid care models, insufficient follow-up, or unmet psychosocial needs (16).

Effective long-term strategies are marked by adaptability. Static treatment regimens tend to underperform when confronted with dynamic life contexts such as job changes, parenting demands, or comorbid condition flare-ups. Modular care models that allow for periodic re-assessment and recalibration have shown greater promise in retaining engagement and improving life quality metrics. Mental health systems that lack continuity between child and adult services often contribute to the treatment gap observed in emerging adults, who frequently experience a drop-off in care during the transitional phase of late adolescence to early adulthood (17). Closing this transition gap involves not only clinical handover but also identity renegotiation, as individuals begin to reinterpret ADHD beyond childhood framing.

Incorporating patient-centered approaches has reshaped how long-term ADHD management is conceptualized. Instead of sole tracking symptom reduction, contemporary frameworks emphasize functioning, autonomy, and personal meaning. Patients consistently report that executive functioning impairments disrupt daily living more than hyperactivity or inattentiveness. These self-defined impairments may not always align with clinician-rated outcomes, underscoring the importance of shared language and collaborative treatment planning. Tools like the WHO's International Classification of Functioning (ICF) have been recommended for structuring care around meaningful activity participation, rather than solely diagnostic symptom clusters (18).

Digital health tools are increasingly being integrated into ADHD care to support self-monitoring, medication adherence, and therapeutic skill retention. Mobile-based applications and ecological momentary assessments offer real-time insights into behavioral patterns, allowing for more responsive care. Some platforms incorporate gamified cognitive tasks, nudging users toward regular engagement. While these tools show preliminary efficacy in supporting long-term management, their impact is mediated by digital literacy, access, and personalization. Automated systems cannot yet replicate the nuance of therapeutic alliance or the contextual understanding gained through ongoing clinician-patient interaction. Nonetheless, digital adjuncts provide scalable extensions of care in resource-limited settings.

Psychosocial support networks remain central to maintaining progress. Adults with ADHD often carry longstanding narratives of failure, rejection, or underachievement, which shape their self-concept and treatment expectations. Psychoeducation groups, peer mentorship, and family-inclusive therapy help reframe these narratives while building external scaffolding for behavior change. Approaches that include identity work, self-advocacy training, and values clarification contribute to improved emotional resilience, particularly in the face of chronic frustration or repeated setbacks. Embedding these elements into the treatment model moves care beyond pathology management toward holistic psychological integration (19).

Conclusion

Effective identification and management of adult ADHD demand nuanced, long-term, and individualized strategies. Diagnostic clarity is often hindered by comorbidities, retrospective symptom recall, and underrecognized presentations. Integrating pharmacological and behavioral treatments improves both symptomatic and functional outcomes. Sustained care hinges on patient-centered models that adapt to evolving life contexts.

Disclosure

Conflict of interest

There is no conflict of interest.

Funding

No funding.

http://dx.doi.org/10.52533/JOHS.2025.51219

Ethical consideration

Non applicable.

Data availability

All data is available within the manuscript.

Author contribution

All authors contributed to conceptualizing, data drafting, collection and final writing of the manuscript.

References

1. Simon V, Czobor P, Bálint S, Mészáros A, Bitter I. Prevalence and correlates of adult attention-deficit hyperactivity disorder: meta-analysis. The British journal of psychiatry. 2009;194(3):204-11.

2. Kessler RC, Adler L, Barkley R, Biederman J, Conners CK, Demler O, et al. The prevalence and correlates of adult ADHD in the United States: results from the National Comorbidity Survey Replication. American Journal of psychiatry. 2006;163(4):716-23.

3. Kooij J, Bijlenga D, Salerno L, Jaeschke R, Bitter I, Balázs J, et al. Updated European Consensus Statement on diagnosis and treatment of adult ADHD. European psychiatry. 2019;56(1):14-34.

4. Safren SA, Sprich S, Mimiaga MJ, Surman C, Knouse L, Groves M, et al. Cognitive behavioral therapy vs relaxation with educational support for medication-treated adults with ADHD and persistent symptoms: a randomized controlled trial. Jama. 2010;304(8):875-80.

5. Quinn PO, Madhoo M. A review of attention-deficit/hyperactivity disorder in women and girls: uncovering this hidden diagnosis. Prim Care Companion CNS Disord. 2014;16(3):PCC. 13r01596.

6. Emilsson B, Gudjonsson G, Sigurdsson JF, Baldursson G, Einarsson E, Olafsdottir H, et al. Cognitive behaviour therapy in medication-treated adults with ADHD and persistent symptoms: a randomized controlled trial. BMC psychiatry. 2011;11(1):116.

7. Asherson P, Buitelaar J, Faraone SV, Rohde LA. Adult attention-deficit hyperactivity disorder: key conceptual issues. The Lancet Psychiatry. 2016;3(6):568-78.

8. Agarwal R, Goldenberg M, Perry R, Ishak WW. The quality of life of adults with attention deficit hyperactivity disorder: a systematic review. Innovations in clinical neuroscience. 2012;9(5-6):10.

9. Rucklidge JJ. Gender differences in ADHD: implications for psychosocial treatments. Expert Review of Neurotherapeutics. 2008;8(4):643-55.

10. Bruchmüller K, Margraf J, Schneider S. Is ADHD diagnosed in accord with diagnostic criteria? Overdiagnosis and influence of client gender on diagnosis. Journal of consulting and clinical psychology. 2012;80(1):128.

11. Young S, Moss D, Sedgwick O, Fridman M, Hodgkins P. A meta-analysis of the prevalence of attention deficit hyperactivity disorder in incarcerated populations. Psychological medicine. 2015;45(2):247-58.

12. Faraone SV, Buitelaar J. Comparing the efficacy of stimulants for ADHD in children and adolescents using meta-analysis. European child & adolescent psychiatry. 2010;19(4):353-64.

13. Caye A, Spadini AV, Karam RG, Grevet EH, Rovaris DL, Bau CH, et al. Predictors of persistence of ADHD into adulthood: a systematic review of the literature and meta-analysis. European child & adolescent psychiatry. 2016;25(11):1151-9.

14. Knouse LE, Safren SA. Current status of cognitive behavioral therapy for adult attention-deficit hyperactivity disorder. The Psychiatric Clinics of North America. 2010;33(3):497.

15. Sibley MH, Kuriyan AB, Evans SW, Waxmonsky JG, Smith BH. Pharmacological and psychosocial treatments for adolescents with ADHD: An updated systematic review of the literature. Clinical psychology review. 2014;34(3):218-32.

http://dx.doi.org/10.52533/JOHS.2025.51219

16. Bolea-Alamañac B, Nutt DJ, Adamou M, Asherson P, Bazire S, Coghill D, et al. Evidence-based guidelines for the pharmacological management of attention deficit hyperactivity disorder: update on recommendations from the British Association for Psychopharmacology. Journal of psychopharmacology. 2014;28(3):179-203.

17. Singh I. A disorder of anger and aggression: Children's perspectives on attention deficit/hyperactivity disorder in the UK. Social science & medicine. 2011;73(6):889-96.

18. DosReis S, Barksdale CL, Sherman A, Maloney K, Charach A. Stigmatizing experiences of parents of children with a new diagnosis of ADHD. Psychiatric Services. 2010;61(8):811-6.

19. Kendall J, Hatton D, Beckett A, Leo M. Children's accounts of attention-deficit/hyperactivity disorder. Advances in nursing science. 2003;26(2):114-30.

http://dx.doi.org/10.52533/JOHS.2025.51219